Home News Page 2

News

Featured Image: Annual Congress of ESMO 2018. Courtesy: © 2018 European Society for Medical Oncology. Used with permission.

ESMO 2019: Seattle Genetics to Present Initial Data from a Phase I Trial Results...

Less than a week before the start of the annual meeting of the European Society for Medical Oncology (ESMO),...
Astellas Pharma, Exhibition booth during ASCO 2019, held May 31 – June 4, 2019 in Chicago, Ill.| Courtsey: Emila Duaerte / Sunvalley Communication

U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced...

The U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for the investigational agent enfortumab...

Glycotope and Tubulis Sign Agreement for ADC Discovery

Glycotope, a clinical stage biotechnology company, and Tubulis, developing uniquely matched protein drug-conjugates,  have signed a research...

Dose Escalation Shows DS-1062 to be Well-tolerated with Partial, Dose-dependent, Responses

Results of a Phase I clinical study and new biomarker data for DS-1062 in 52 unselected patients...

Late-breaking Results: HER3 Targeting U3-1402 in Patients with Metastatic EGFR Mutated, TKI Resistant NSCLC...

Updated phase I data for U3-1402, an investigational HER3 targeting antibody-drug conjugate or ADC being developed by...

Daiichi Sankyo Submits New Drug Application for Trastuzumab Deruxtecan to Japanese Regulators

Earlier this week Daiichi Sankyo confirmed this week that it has submitted a New Drug Application (NDA)...
Justin Sweeley, Novasep

Webinar: When to Apply Design of Experiments (DoE) to ADC Development

Live Webinar: When to Apply Design of Experiments (DoE) to ADC Development Date: September 24, 2019 Time: 8AM PDT / 5PM...

Anti-VEGF antibody biopolymer conjugate KSI-301 in Treatment of Retinal Vascular Diseases Shows Encouraging Results...

This weekend results from novel therapeutics to treat chronic, high-prevalence retinal diseases, were presented during the European...

FDA Clears IND Application for Phase I/II Study of OBI-999 in Epithelial Cancer

Earlier this week the U.S. Food and Drug Administration (FDA) cleared an investigational new drug (IND) application...

Strategic Alliance Helps the Development Antibody Fragment-Drug Conjugates

In August 2019 Antikor Biopharma and Essex Bio-Technology confirmed that the companies had entered into an investment...

FEATURED RESOURCES